1.Males or females over or equal 18 years of age and over or equal 40 kg at the time of providing informed consent2.Confirmed diagnosis of SARS-CoV-2 infection presenting as severe COVID-19 requiring hospitalization3.Severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography (CT) or X-ray at Screening or within the 3 days prior to Screening, as part of the patient's routine clinical care4.Severe pneumonia, acute lung injury, or acute respiratory distress syndrome requiring oxygen supplementation with invasive or noninvasive mechanical ventilation5.Female patients of childbearing potential and male patients with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug

1.Males or females over or equal 18 years of age and over or equal 40 kg at the time of providing informed consent2.Confirmed diagnosis of SARS-CoV-2 infection presenting as severe COVID-19 requiring hospitalization3.Severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography (CT) or X-ray at Screening or within the 3 days prior to Screening, as part of the patient's routine clinical care4.Severe pneumonia, acute lung injury, or acute respiratory distress syndrome requiring oxygen supplementation with invasive or noninvasive mechanical ventilation5.Female patients of childbearing potential and male patients with female partners of childbearing potential must follow protocol specified contraception guidance for avoiding pregnancy for 8 months after treatment with the study drug